Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACT-128800 Dose 1 · 1 trial · 1 indication
Cumulative Number of new T1 gadolinium-enhancing (Gd+) lesions per year on magnetic resonance imaging (MRI) scan from Week 12 to Week 24 were reported. Negative binomial (NB) regression analysis on Per protocol analysis set and imputation was applied for the missing data. Here, MS signifies multiple sclerosis.
| Arm | Type | Description |
|---|---|---|
| ACT-128800 Dose 1 | EXPERIMENTAL | ACT-128800 Dose 1 |
| ACT-128800 Dose 2 | EXPERIMENTAL | ACT-128800 Dose 2 |
| ACT-128800 Dose 3 | EXPERIMENTAL | ACT-128800 Dose 3 |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| ACT-128800 Dose 1 | DRUG | ACT-128800 (Dose 1) administered orally once daily |
| Placebo | DRUG | Matching placebo administered orally once daily |
| ACT-128800 Dose 2 | DRUG | ACT-128800 (Dose 2) administered orally once daily |
| ACT-128800 Dose 3 | DRUG | ACT-128800 (Dose 3) administered orally once daily |
Inclusion Criteria: * Adult males and females * Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS). * Signed inform consent prior to initiation of any study-mandated procedure. Exclusion Criteria: * A diagnosis of MS categorized as primary ...
ACT-128800 Dose 1 is an investigational small molecule being studied for the treatment of relapsing-remitting multiple sclerosis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its efficacy, safety, and tolerability in patients with this condition.
ACT-128800 Dose 1 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential to treat relapsing-remitting multiple sclerosis, though the exact mechanism of action is not publicly detailed.
ACT-128800 Dose 1 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with relapsing-remitting multiple sclerosis.
ACT-128800 Dose 1 is in Phase 2 clinical development. It is an investigational drug and has not received approval from regulatory agencies. The Phase 2 trial has been completed, and the drug is not currently in active clinical trials, according to available data.
ACT-128800 Dose 1 has been studied in one completed Phase 2 clinical trial with the identifier NCT01006265. This randomized, double-blind, placebo-controlled study enrolled 464 participants with relapsing-remitting multiple sclerosis across multiple countries, including the United States, Canada, and European nations.
ACT-128800 Dose 1 is a specific dose level of the drug ACT-128800. The clinical trial NCT01006265 evaluated the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis, with ACT-128800 Dose 1 representing one of the doses tested in the study.